

[Anatomic Pathology Abstracts, 4/16](#)

written by CAP TODAY

April 20, 2016

April 2016—Comparison of methods for analyzing gene amplification in gastric cancers; Uterine smooth muscle tumor analysis by comparative genomic hybridization; Role of TAZ in aggressive types of endometrial cancer; Reclassification of resected lung carcinomas diagnosed as squamous cell carcinoma; Sequencing of cancer genes in ampullary carcinoma shows trends in histologic subtypes; Prognostic significance of the 2014 ISUP grading system for prostate cancer



©2026 CAP TODAY, all rights reserved.

[Q&A column, 4/16](#)

written by CAP TODAY

April 20, 2016

April 2016—We review peripheral blood smears and sometimes provide recommendations. For microcytic anemia with high red blood cell count, iron study and hemoglobin electrophoresis are suggested to rule out hemoglobinopathy. But for cases of microcytosis with high RBC count but without anemia, should we give the same recommendation as for an anemic patient?



©2026 CAP TODAY, all rights reserved.

[Newsbytes, 4/16](#)

written by CAP TODAY
April 20, 2016

April 2016—Finding, fixing, and foiling shadow IT problems: The unsanctioned use of mobile devices and cloud-based software in the workplace, often referred to as shadow IT, is a pervasive problem. Yet, through education and enforcement of policies, it's a problem that can be minimized.



©2026 CAP TODAY, all rights reserved.

[Beyond connectivity: middleware's shifting shape](#)

written by CAP TODAY
April 20, 2016

April 2016—Middleware was always about connectivity. But when it emerged on the scene some 20 years ago, connectivity involved basically one mandate: getting laboratory instruments to talk electronically to a hospital's laboratory information system, accept orders, and deliver results to the right shelves in the LIS warehouse.



©2026 CAP TODAY, all rights reserved.

In memoriam: Thomas P. Wood, MD | 1929-2016

written by CAP TODAY
April 20, 2016

April 2016—Thomas P. Wood, MD, the 25th president of the CAP, died Feb. 15 at age 87. Dr. Wood was speaker of the House of Delegates from 1992 to 1995, president-elect from 1995 to 1997, and president from 1997 to 1999. He was a longtime member of the Professional Affairs Committee (which he also chaired) and the Council on Government and Professional Affairs, and he was a board director of the CAP Foundation for six years. In 2000, the CAP recognized him as Pathologist of the Year.



©2026 CAP TODAY, all rights reserved.

Put It on the Board, 4/16

written by CAP TODAY
April 20, 2016

April 2016—Logistics hurdles overcome for single Pap-HPV report: Is one test better than two? That question—primary HPV versus the Pap-HPV cotesting option—has roiled the world of cervical cancer screening since the Food and Drug Administration approved a primary HPV screening test in April 2014. However clinicians decide to answer that question, this much is clear: A single report is better than two separate results.



©2026 CAP TODAY, all rights reserved.

[Zika virus detection test, 4/16](#)

written by CAP TODAY
April 20, 2016

April 2016—Euroimmun, headquartered in Luebeck, Germany, has developed a system of comprehensive tests available for the serological detection and differentiation of Zika virus infections.



©2026 CAP TODAY, all rights reserved.

[Swift, SeraCare partner on ctDNA standards, 4/16](#)

written by CAP TODAY
April 20, 2016

April 2016—Swift Biosciences and SeraCare Life Sciences will partner to accelerate development of a novel circulating tumor DNA reference material.



©2026 CAP TODAY, all rights reserved.

[Telepathology solution, 4/16](#)

written by CAP TODAY
April 20, 2016

April 2016—Mikrosan Technologies released the SL5, a real-time telepathology and whole slide imaging solution for use in anatomic pathology applications.



©2026 CAP TODAY, all rights reserved.

[Myriad expands collaboration with Tesaro and Merck, 4/16](#)

written by CAP TODAY
April 20, 2016

April 2016—Myriad Genetics announced a strategic research collaboration with Tesaro and Merck (known as MSD outside the U.S. and Canada) to help identify potential responders to an investigational combination drug therapy using Tesaro's PARP inhibitor (niraparib) plus Keytruda (pembrolizumab), Merck's anti-PD-1 therapy.



©2026 CAP TODAY, all rights reserved.